Last Chance to Invest in Emerald Health Pharmaceutical’s Private Financing

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Emerald Health Pharmaceuticals is a science-based company that uses the unique convergence of science, biology, and cannabis molecules like Cannabidiol (CBD) and Cannabigerol (CBG) to create new molecules – which can elicit beneficial effects (that CBD doesn’t) to potentially treat so-far incurable diseases.

This company is distinct from the public company we have interviewed before: Emerald Health Therapeutics Inc (CVE:EMH) (OTCMKTS:EMHTF) (FRA:TBD) – the Canadian company involved in the CBD based technology of growing and extracting. Both of these companies are partially owned by Emerald Health Sciences (hence the name).

EHP is a private company based in the U.S. that creates unique compounds using CBD and CBG, which are scientifically and chemically manipulated to affect certain biologic pathways and receptors in the human body. The new molecules are validated to stop the progression, reverse, and even cure a number of targeted, rare and incurable diseases.

The company has Stage II human clinical trials underway involving serious diseases like Multiple Sclerosis, Systemic Sclerosis, Parkinson’s disease, and Huntington’s disease. EHP’s two molecules, EHP-101 and EHP-102, have composition patents and have been granted designations.

“CBD has known health benefits, anti-inflammation benefits but won’t change the course of progression of these rare diseases. Because [Emerald Health Pharmaceutical’s] molecules have been changed specifically to affect pathways in the body that are specific for treating Multiple Sclerosis, Parkinson’s, etc. This will stop the progression of the disease and can also reverse the disease.” – Jim DeMesa MD, MBA – Emerald Health Pharmaceuticals CEO

The company currently has Regulation A financing underway which gives people the opportunity to invest in the private company. EHP has announced the final closing date for this offering of March 28 by midnight. To date, EHP has received investment commitments of approximately $56.0 million from over 8,000 investors.

Watch the full interview for an outline of the company, how Emerald’s differentiated CBD/CBG molecules work, the diseases they are helping, and how to invest.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.